# CALL FOR PROPOSALS

# BioCanRx v2.0: Setting the stage for Network Renewal

### LETTER OF INTENT APPLICATION FORM

The completed Letter of Intent (LOI) application must be delivered by email to applications@biocanrx.com and must be received by 11:59 am ET, on May 1, 2019.

Please direct questions about the program and application process to Jennifer Quizi (BioCanRx Director, Scientific Affairs, jquizi@biocanrx.com, (613-739-6716) or Stéphanie Michaud (BioCanRx President and Chief Executive Officer, smichaud@biocanrx.com (613-739-6202).

### Document 1

Please complete the Letter of Intent Application Form in single-spaced type, Times New Roman or Arial (minimum 11 pt font), with one-inch margins. Please enter the project leader’s name and institution in the header but do not modify the rest of the header. You may delete the specific section instructions but do not delete section headings. The file name should include the Project Leader’s name and date (e.g. Bell\_LOI\_May 1\_2019.pdf) and be saved in PDF format.

### SECTION 1: PROJECT OVERVIEW

**Proposal Title:**

**Funding Opportunity (only 1 funding program per LOI submission)**

 **🞏 Enabling Studies Program**

 **🞏 Clinical Trial Program**

 **🞏 Clinical, Social, and Economic Impact Program**

 **🞏 Core Facilities Program**

**Cycle II Priority Area(s) Addressed (check all that apply)**

**🞏 Identifying solid tumour targets for adoptive cell therapy**

**🞏 Turning “cold” tumours “hot”**

**🞏 Identifying or validating mechanisms of resistance of tumours to immunotherapy in the clinical setting (cellular, immunological, genomic, biomarkers, pathway obstacles, microenvironment)**

**🞏 Biologically relevant cancer targeting (pathways, tumour microenvironment elements, immune cell subsets).**

**🞏 Developing or refining combination approaches;**

**🞏 Designing and Creating Multiplex Immunotherapeutics**

**🞏 Early health technology assessments (HTA) and/or policy frameworks to support the development of novel biotherapeutics and/or combination therapy approaches**

**Alignment with Current BioCanRx Portfolio:**

The BioCanRx portfolio of research investments can be viewed here:

<https://biocanrx.com/research/research-program>

Please indicate to which project(s), technology(ies), or platform(s) the proposed project concept aligns and briefly describe the value add of the proposed project to the future development of the BioCanRx portfolio (150 words max).

**\*Important:** If this project was previously funded by BioCanRx and is graduating to the next stage in the pipeline, e.g. previously funded as a catalyst and now requesting funding as an enabling study, please list the previously supported proposal title, amount and duration here.

**Linkages to other LOI submissions:**

Is this proposal linked with another complementary submission to another program? If so, name the project and project leader for the linked proposal here:

**Projected Period of Support:** (dd/mm/yyyy) to (dd/mm/yyyy): Pick a period that most accurately reflects the expected time over which the project will be conducted. Note that new projects in Cycle II can start to receive funds as of **April 1, 2020**. **Please note that all projects must be completed no later than March 31st, 2023**.

**Project Leader:** Identify one network investigator who will be responsible for overseeing management of the project, including allocation of project budgets and progress reporting to BioCanRx. Also indicate the host institution:

**Team Members:** In Table I below, list all proposed Principal Investigators involved in the project. For each person, provide their name, position, institutional affiliation and email address. Do not include trainees and personnel. Add rows as needed.

#### Table I: Project Investigators

Indicate Principal Investigators (PIs) participating in the project.

|  |  |
| --- | --- |
| **Principal Investigator**  | **Role in Project/Expertise** |
| Name, position, institution, email address |  |
|  |  |
|  |  |
|  |  |
|  |  |
|  |  |

**Budget**: In Table II below (adding lines as necessary), list the amount requested from BioCanRx by Principle Investigator and each confirmed partner that will support the proposed translational acceleration project. Detail the amount ($) and nature of support provided. It is expected that each project will secure 50% of total project funds from partners, although not all of this funding needs to be secured at the time of submission.

#### Table II: Project Budget

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Principal Investigator**  | **Total Amount of Requested BioCanRx Funds** | **Total Amount of Partnering Funds**  | **Type of Partner Funds (cash, in-kind, cash and in-kind)** | **Total Amount of Project Funding** |
| Name |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
| **TOTAL** |  |  |  |  |

**SECTION 2: SCIENTIFIC SUMMARY**

In one (1) page maximum:

1. Describe the background, rationale and objectives of the project.
2. Highlight the international competitiveness and innovative nature of the proposed technology. Also provide comment on potential technological, clinical and/or commercial impact of the proposed project. **Highlight the contribution of the proposed work to the advancement of BioCanRx technology(ies), and how this project addresses areas of priority focus for BioCanRx.**
3. Comment on the potential benefits of the application of this research to Canada and to the BioCanRx network.
4. Describe the overall deliverable of the project and make the case for BioCanRx to showcase the proposal in the NCE renewal application.

### SECTION 3: PARTNERSHIPS

In Table III below (adding lines as necessary), list each partner that is anticipated to support the proposed project. Please also add partners or partner organizations/stakeholders that could facilitate the conduct or translation of the outcomes of this work, if engaged by the project team, or by BioCanRx. Although Letters of Support from industry partners are not required for the LOI submission date, LOIs selected will be required to secure letters of support by no later than **June 14th, 2019** to include as part of the BioCanRx renewal application. Please note here whether:

1) a letter of support has been secured and is included as part of this LOI submission;

2) a letter of support has not yet been secured but can be upon selection of this LOI; or

3) a letter of support will not be able to be secured.

Please note that the three federal granting councils (CIHR, NSERC and SSHRC), other NCEs, CFI and Genome Canada **are not** eligible partners for the purpose of this competition.

#### Table III: Partners

|  |  |
| --- | --- |
| Name of Partner | Actual, anticipated, or desired partner? |
| 1. |  |
| Role in Project:Potential Conflict of Interest?Status of Letter of Support: |
| 2.  |  |
| Role in Project:Potential Conflict of Interest?Status of Letter of Support: |
| 3. |  |
| Role in Project:Potential Conflict of Interest?Status of Letter of Support: |
| 4. |  |
| Role in Project:Potential Conflict of Interest?Status of Letter of Support: |

### SECTION 5: FUTURE PRODUCT/PLATFORM DEVELOPMENT TRAJECTORY

A key objective of BioCanRx funding is to accelerate the translation of cancer biotherapeutic innovations from the laboratory through to early phase clinical evaluation, with the ultimate goal of delivering products and platforms for commercialization, and market access to cancer patients. In **150 words maximum**, describe the anticipated next steps in technological advancement or clinical and/or commercial development of the product(s) and/or platform(s) in the proposed study. Describe the intellectual property status of the technology and include a realistic assessment of the likelihood of industry partner engagement and the role of prospective partners in future development of your product/platform. Also, discuss any additional partners from other sectors (NGO, consortia), which might be required to realize these later stage development goals.